![]() ![]() trastuzumab emtansine in patients with HER2 positive metastatic breast cancer: updated survival results of the randomized, phase 3 study DESTINY-Breast03 treatment of physician’s choice in patients with HER2 positive unresectable and/or metastatic breast cancer previously treated with trastuzumab emtansine: primary results of the phase 3 study DESTINY-Breast02 Highlights of the data from the DXd ADC portfolio of Daiichi Sankyo to be presented at SABCS 2022 include:ĮNHERTU (trastuzumab deruxtecan/T-DXd HER2 directed ADC) Company executives will provide an overview of Daiichi Sankyo’s research data presented at SABCS, provide updates on the company’s R&D strategy, and address questions from investors and analysts. In patients with metastatic triple negative breast cancer (TNBC), updated results from the TROPION-PanTumor01 phase 1 trial of datopotamab deruxtecan will be featured as a poster presentation and a Spotlight Poster Discussion will provide updated data from the datopotamab deruxtecan and durvalumab arm of the BEGONIA phase 1b/2 trial.Īdditionally, updates from other ongoing breast cancer trials from the DESTINY and TROPION clinical development programs of ENHERTU and datopotamab deruxtecan as well as collaborative trials across Daiichi Sankyo’s DXd ADC portfolio including DEBBRAH, TRIO-US B-12 TALENT and SOLTI-TOT-HER3 will be presented.įollowing SABCS, Daiichi Sankyo will hold its annual R&D Day for investors and analysts on Monday, Decemat 5:30 pm ET. With these new data, Daiichi Sankyo continues reaching for our goal of changing the standard of care for patients across all breast cancer subtypes with our innovative DXd ADC portfolio.” “We will present for the first time preliminary data of datopotamab deruxtecan in patients with HR positive, HER2 negative metastatic breast cancer, as well as updated results in metastatic triple negative breast cancer. “Three years after unveiling the impressive results of DESTINY-Breast01 at SABCS, we look forward to showcasing data from two additional head-to-head trials confirming the efficacy and safety profile of ENHERTU, including updated results from DESTINY-Breast03 and the first presentation of results from DESTINY-Breast02,” said Ken Takeshita, MD, Global Head, R&D, Daiichi Sankyo. A Spotlight Poster Discussion will feature the first reported results of datopotamab deruxtecan (Dato-DXd) in patients with HR positive, HER2 negative metastatic breast cancer from the TROPION-PanTumor01 phase 1 trial. Annual R&D Day following SABCS to provide updates across Daiichi Sankyo R&D portfolioīasking Ridge, NJ – (November 21, 2022) – Daiichi Sankyo (TSE: 4568) continues to boldly challenge the breast cancer treatment landscape with the presentation of 30 abstracts from its innovative DXd antibody drug conjugate (ADC) portfolio at the 2022 San Antonio Breast Cancer Symposium (#SABCS22) to be held December 6 to 10, 2022.ĮNHERTU ® (trastuzumab deruxtecan) data from DESTINY-Breast03 and DESTINY-Breast02, two head-to-head phase 3 trials in patients with previously treated HER2 positive metastatic breast cancer, will be highlighted in back-to-back oral presentations and included in the SABCS Press Program.First presentation of datopotamab deruxtecan results in patients with HR positive, HER2 negative metastatic breast cancer shows promising clinical activity.Survival data from DESTINY-Breast03 and DESTINY-Breast02 phase 3 trials in patients with HER2 positive metastatic breast cancer further confirms efficacy of ENHERTU.External Sponsored Research (ESR) Investigator Initiated Studies (IIS) and Collaborative Research (CR)ĭata Across Daiichi Sankyo DXd ADC Portfolio at 2022 SABCS Demonstrates Bold Progress in Advancing Treatment for Patients with Breast Cancer.Expanded Access to Investigational Products. ![]() Rights & Protections Against Surprise Medical Bills.Daiichi Sankyo Patient Support Programs.Vermont Pharmaceutical Marketer Price Disclosure.CME and Charitable Contributions Disclosure.Daiichi Sankyo Group Global Business Partner Code of Conduct.Daiichi Sankyo Group Global Anti-Bribery and Anti-Corruption Policy.Standards of Business Conduct & Ethics for Third Parties. ![]() Company Governance and Global Structure.Global Business Strategy and Midterm Plan. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |